

POEM Retinoblastoma Protocol-1 (P-RET-1)

Description

A Regional treatment protocol for participants with Intra Ocular Retinoblastoma in the POEM region.

Collaborating Centers

1. King Hussein Cancer Center (KHCC) - Jordan
2. Children's Cancer Center of Lebanon (CCCL)
3. The American University of Beirut Medical Center (AUBMC)

Primary Objectives

1. To determine the feasibility of a multi-center, prospective clinical trial for the treatment of intraocular retinoblastoma in the POEM region.
 - a. The ability to accrue on treatment regimen-based retinoblastoma treatment in POEM.
 - b. The adherence to treatment regimen-based retinoblastoma treatment in POEM
2. To evaluate the use of Topotecan systemic chemotherapy for patients with advanced intraocular bilateral Retinoblastoma or unilateral RB not requiring upfront enucleation and foveal sparing disease.
 - a. Document observed systemic toxicity.
 - b. Evaluate whether routine use of filgrastim care can manage observed toxicities with minimally incurred morbidity.
 - c. Evaluate the ocular survival rate (avoidance of enucleation or radiation) using treatment regimens that include Topotecan systemic chemotherapy.

Secondary Objectives

To describe the clinical outcome of patients with intraocular retinoblastoma using the international classification for the Intraocular Retinoblastoma grouping system.

1. Patient abandonment
2. Patient survival
3. Visual outcome.
4. Accuracy and consistency of Audiologic testing, and audiologic outcome
5. Correlate outcome of Topotecan recommended dosing with the published Topotecan
6. Pharmacokinetics (PK) studies.

Protocol Status

In preparation (not open yet)

Investigators

Primary: Dr. Yacoub A. Yousef, KHCC - Jordan

Co-Primary: Dr. Raya Saab, AUBMC - Lebanon